| Literature DB >> 28046022 |
Mirosława Studzińska1, Agnieszka Jabłońska1, Małgorzata Wiśniewska-Ligier2, Dorota Nowakowska3, Zuzanna Gaj3, Zbigniew J Leśnikowski1, Teresa Woźniakowska-Gęsicka4, Jan Wilczyński5, Edyta Paradowska1.
Abstract
Intracellular Toll-like receptor 3 (TLR3) recognizes viral double-stranded RNA (dsRNA) and activates antiviral immune responses through the production of type I interferons (IFNs) and inflammatory cytokines. This receptor binds to dsRNA molecules produced during human cytomegalovirus (HCMV) replication. TLR7 senses viral single-stranded RNA (ssRNA) in endosomes, and it can interact with endogenous RNAs. We determined the genotype distribution of single-nucleotide polymorphisms (SNPs) within the TLR3 and TLR7 genes in children with HCMV infection and the relationship between TLR polymorphisms and viral infection. We genotyped 59 children with symptomatic HCMV infection and 78 healthy individuals for SNPs in the TLR3 (rs3775290, c.1377C>T, F459F; rs3775291, c.1234C>T, L412F; rs3775296, c.-7C>A) and TLR7 (rs179008, c.32A>T, Q11L; rs5741880, c.3+1716G>T) genes. SNP genotyping was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and capillary electrophoresis. The HCMV DNA load was quantified by real-time PCR. We found an increased frequency of the heterozygous genotype TLR3 L412F in children with HCMV infection compared with uninfected cases. In individuals with a mutation present in at least one allele of the L412F SNP, an increased risk of HCMV disease was found, and this result remained highly significant after Bonferroni's correction for multiple testing (Pc < 0.001). The heterozygous genotype of this SNP was associated with the increased risk of HCMV disease in an adjusted model that included the HCMV DNA copy number in whole blood and urine (P < 0.001 and P = 0.008, respectively). Moreover, those with a heterozygous genotype of rs3775296 showed an increased relative risk of HCMV infection (P = 0.042), but this association did not reach statistical significance after correction for multiple testing. In contrast, the rs3775290 SNP of TLR3 and TLR7 SNPs were not related to viral infection. A moderate linkage disequilibrium (LD) was observed between the SNPs rs3775291 and rs3775296 (r2 = 0.514). We suggest that the L412F polymorphism in the TLR3 gene could be a genetic risk factor for the development of HCMV disease.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28046022 PMCID: PMC5207783 DOI: 10.1371/journal.pone.0169420
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic and clinical characteristics of study subjects with HCMV infection.
| Characteristics | |
|---|---|
| 59 | |
| 5.7 ± 5.3 | |
| 4 (1–24) | |
| Female | 20 (33.9) |
| Male | 39 (66.1) |
| Hematological disorders | 25 (42.4) |
| Pneumonia | 16 (27.1) |
| Liver damage or hepatitis | 15 (25.4) |
| Neurological dysfunction | 15 (25.4) |
| CNS damage | 14 (23.7) |
| Psychomotor retardation | 12 (20.3) |
| Jaundice | 11 (18.6) |
| Hearing loss | 6 (10.2) |
| IUGR | 5 (8.5) |
| Hepatosplenomegaly | 5 (8.5) |
| Heart disease | 2 (3.4) |
| IgG-positive, IgM-negative | 25 (42.4) |
| IgG-positive, IgM-positive | 32 (54.2) |
| IgG-negative, IgM-negative | 2 (3.4) |
aValues are the number of infants (%).
Selected single-nucleotide polymorphisms in the TLR3 and TLR7 genes.
| Gene | SNP ID | Alleles | Amino acid change | Function | MAF | ||
|---|---|---|---|---|---|---|---|
| Polish | European | Global | |||||
| rs3775290 | C/T | F459F | Silent | 0.321 | 0.273 | 0.272 | |
| rs3775291 | C/T | L412F | Missense | 0.256 | 0.324 | 0.232 | |
| rs3775296 | C/A | UTR-5 | 0.173 | 0.174 | 0.182 | ||
| rs179008 | A/T | Q11L | Missense | 0.301 | 0.176 | 0.118 | |
| rs5741880 | G/T | Intronic | 0.308 | 0.092 | 0.207 | ||
MAF, Minor allele frequency in the Polish population (present study), European and Global population (NCBI, 1000 Genomes Project)
Restriction enzymes and length of the restriction fragments.
| Gene | SNP | Restriction enzyme | Genotype | Length of the restriction fragments (bp) |
|---|---|---|---|---|
| rs3775290 | CC | 39, 45, 299 | ||
| CT | 39, 45, 299, 383 | |||
| TT | 383 | |||
| rs3775291 | CC | 31,169 | ||
| CT | 31, 169, 200 | |||
| TT | 200 | |||
| rs3775296 | CC | 285 | ||
| CA | 37, 52, 196, 285 | |||
| AA | 37, 52, 196 | |||
| rs179008 | AA | 64, 116, 174 | ||
| AT | 64, 116, 174, 247 | |||
| TT | 174, 247 | |||
| rs5741880 | GG | 186 | ||
| GT | 43, 143, 186 | |||
| TT | 43, 143 |
bp, base pairs
Fig 1Visualization of PCR-RFLP products for TLR3 SNP (A) and TLR7 SNP (B) genotyping.
Gel image: A) rs3775290: 1. wild type CC, 2. heterozygous CT, 3. homozygous recessive TT; rs3775291: 4. wild type CC, 5. heterozygous CT, 6. homozygous recessive TT; rs3775296: 7. wild type CC, 8. heterozygous CA, 9. homozygous recessive AA. B) rs179008: 1. wild type AA, 2. heterozygous AT, 3. homozygous recessive TT; rs5741880: 4. wild type GG, 5. heterozygous GT, 6. homozygous recessive TT. Alignment markers (15 bp, 1 kbp).
Frequency and distribution of TLR genotypes and their association with HCMV infection.
| Gene | SNP | Model | Genotype | Genotype frequencies; n (%) | Unadjusted | Adjusted | |||
|---|---|---|---|---|---|---|---|---|---|
| HCMV-infected | Uninfected | OR (95% CI) | OR (95% CI) | ||||||
| rs121917864 | Codominant | CC | 59 (100%) | 77 (98.7%) | 1.00 | 0.29 | 1.00 | 0.48 | |
| CT | 0 (0%) | 1 (1.3%) | 0.00 (0.00-NA) | 0.00 (0.00-NA) | |||||
| rs5743708 | Codominant | GG | 57 (96.6%) | 78 (100%) | 1.00 | 0.065 | 1.00 | NA | |
| GA | 2 (3.4%) | 0 (0%) | NA (0.00-NA) | NA (0.00-NA) | |||||
| rs3775290 | Codominant | CC | 24 (40.7) | 38 (48.7) | 1.00 | 0.33 | 1.00 | 0.042 | |
| CT | 30 (50.9) | 30 (38.5) | 1.58 (0.77–3.25) | 3.17 (1.10–9.15) | |||||
| TT | 5 (8.5) | 10 (12.8) | 0.79 (0.24–2.60) | 0.63 (0.07–5.88) | |||||
| Dominant | CC | 24 (40.7) | 38 (48.7) | 1.00 | 0.35 | 1.00 | 0.068 | ||
| CT-TT | 35 (59.3) | 40 (51.3) | 1. 39 (0.70–2.74) | 2.53 (0.90–7.15) | |||||
| Recessive | CC-CT | 54 (91.5) | 68 (87.2) | 1.00 | 0.41 | 1.00 | 0.23 | ||
| TT | 5 (8.5) | 10 (12.8) | 0.63 (0.20–1.95) | 0.32 (0.04–2.68) | |||||
| Overdominant | CC-TT | 29 (49.1) | 48 (61.5) | 1.00 | 0.15 | 1.00 | 0.013 | ||
| CT | 30 (50.9) | 30 (38.5) | 1.66 (0.83–3.28) | 3.43 (1.25–9.38) | |||||
| rs3775291 | Codominant | CC | 5 (8.5) | 46 (59.0) | 1.00 | 1.00 | |||
| CT | 49 (83.0) | 24 (30.8) | 18.78 (6.61–53.36) | 11.50 (3.08–42.97) | |||||
| TT | 5 (8.5) | 8 (10.2) | 5.75 (1.35–24.49) | 1.92 (0.18–20.80) | |||||
| Dominant | CC | 5 (8.5) | 46 (59.0) | 1.00 | 1.00 | ||||
| CT-TT | 54 (91.5) | 32 (41.0) | 15.52 (5.59–43.11) | 9.10 (2.48–33.36) | |||||
| Recessive | CC-CT | 54 (91.5) | 70 (89.7) | 1.00 | 0.72 | 1.00 | 0.38 | ||
| TT | 5 (8.5) | 8 (10.3) | 0.81 (0.25–2.62) | 0.42 (0.05–3.52) | |||||
| Overdominant | CC-TT | 10 (16.9) | 54 (69.2) | 1.00 | 1.00 | ||||
| CT | 49 (83.1) | 24 (30.8) | 11.02 (4.79–25.36) | 10.13 (3.09–33.13) | |||||
| rs3775296 | Codominant | CC | 32 (54.2) | 55 (70.5) | 1.00 | 0.12 | 64 | 0.55 | |
| CA | 24 (40.7) | 19 (24.4) | 2.17 (1.03–4.56) | 1.78 (0.64–4.96) | |||||
| AA | 3 (5.1) | 4 (5.1) | 1.29 (0.27–6.13) | 1.06 (0.11–10.27) | |||||
| Dominant | CC | 32 (54.2) | 55 (70.5) | 1.00 | 0.05 | 1.00 | 0.32 | ||
| CA-AA | 27 (45.8) | 23 (29.5) | 2.02 (1.00–4.09) | 1.66 (0.62–4.41) | |||||
| Recessive | CC-CA | 56 (94.9) | 74 (94.9) | 1.00 | 0.99 | 1.00 | 0.91 | ||
| AA | 3 (5.1) | 4 (5.1) | 0.99 (0.21–4.61) | 0.88 (0.09–8.31) | |||||
| Overdominant | CC-AA | 35 (59.3) | 59 (75.6) | 1.00 | 0.042 | 1.00 | 0.27 | ||
| CA | 24 (40.7) | 19 (24.4) | 2.13 (1.02–4.43) | 1.77 (0.65–4.88) | |||||
| rs179008 | Codominant | AA | 35 (59.3) | 39 (50.0) | 1.00 | 0.51 | 1.00 | 0.5 | |
| AT | 18 (30.5) | 31 (39.7) | 0.65 (0.31–1.35) | 0.54 (0.19–1.57) | |||||
| TT | 6 (10.2) | 8 (10.3) | 0.84 (0.26–2.65) | 0.70 (0.13–3.68) | |||||
| Dominant | AA | 35 (59.3) | 39 (50.0) | 1.00 | 0.28 | 1.00 | 0.25 | ||
| AT-TT | 24 (40.7) | 39 (50.0) | 0.69 (0.35–1.36) | 0.57 (0.22–1.52) | |||||
| Recessive | AA-AT | 53 (89.8) | 70 (89.7) | 1.00 | 0.99 | 1.00 | 0.87 | ||
| TT | 6 (10.2) | 8 (10.3) | 0.99 (0.32–3.03) | 0.87 (0.17–4.45) | |||||
| Overdominant | AA-TT | 41 (69.5) | 47 (60.3) | 1.00 | 0.26 | 1.00 | 0.28 | ||
| AT | 18 (30.5) | 31 (39.7) | 0.67 (0.33–1.36) | 0.57 (0.20–1.61) | |||||
| rs5741880 | Codominant | GG | 24 (40.7) | 37 (47.4) | 1.00 | 0.57 | 1.00 | 0.17 | |
| GT | 31 (52.5) | 34 (43.6) | 1.41 (0.69–2.85) | 0.36 (0.12–1.11) | |||||
| TT | 4 (6.8) | 7 (9.0) | 0.88 (0.23–3.34) | 0.70 (0.13–3.79) | |||||
| Dominant | GG | 24 (40.7) | 37 (47.4) | 1.00 | 0.43 | 1.00 | 0.082 | ||
| GT-TT | 35 (59.3) | 41 (52.6) | 1.32 (0.66–2.61) | 0.42 (0.15–1.15) | |||||
| Recessive | GG-GT | 55 (93.2) | 71 (91.0) | 1.00 | 0.64 | 1.00 | 0.99 | ||
| TT | 4 (6.8) | 7 (9.0) | 0.74 (0.21–2.65) | 1.01 (0.20–5.27) | |||||
| Overdominant | GG-TT | 28 (47.5) | 44 (56.4) | 1.00 | 0.3 | 1.00 | 0.068 | ||
| GT | 31 (52.5) | 34 (43.6) | 1.43 (0.73–2.83) | 0.38 (0.13–1.14) | |||||
| rs5743836 | Codominant | TT | 58 (98.3%) | 78 (100%) | 1.00 | 0.19 | 1.00 | 0.08 | |
| CC | 1 (1.7%) | 0 (0%) | NA (0.00-NA) | NA (0.00-NA) | |||||
| rs187084 | Codominant | TT | 17 (28.8%) | 31 (39.7%) | 1.00 | 0.085 | 1.00 | 0.096 | |
| TC | 36 (61%) | 33 (42.3%) | 1.99 (0.93–4.24) | 2.82 (0.92–8.68) | |||||
| CC | 6 (10.2%) | 14 (17.9%) | 0.78 (0.25–2.41) | 0.89 (0.15–5.13) | |||||
| Dominant | TT | 17 (28.8%) | 31 (39.7%) | 1.00 | 0.18 | 1.00 | 0.13 | ||
| TC-CC | 42 (71.2%) | 47 (60.3%) | 1.63 (0.79–3.36) | 2.24 (0.75–6.71) | |||||
| Recessive | TT-TC | 53 (89.8%) | 64 (82%) | 1.00 | 0.19 | 1.00 | 0.29 | ||
| CC | 6 (10.2%) | 14 (17.9%) | 0.52 (0.19–1.44) | 0.46 (0.10–2.19) | |||||
| Overdominant | TT-CC | 23 (39%) | 45 (57.7%) | 1.00 | 0.03 | 1.00 | 0.031 | ||
| TC | 36 (61%) | 33 (42.3%) | 2.13 (1.07–4.25) | 2.92 (1.07–7.97) | |||||
| rs352139 | Codominant | AA | 33 (55.9%) | 25 (32%) | 1.00 | 1.00 | 0.035 | ||
| GA | 23 (39%) | 34 (43.6%) | 0.51 (0.24–1.08) | 0.55 (0.20–1.51) | |||||
| GG | 3 (5.1%) | 19 (24.4%) | 0.12 (0.03–0.45) | 0.11 (0.01–0.92) | |||||
| Dominant | AA | 33 (55.9%) | 25 (32%) | 1.00 | 0.005 | 1.00 | 0.057 | ||
| GA-GG | 26 (44.1%) | 53 (68%) | 0.37 (0.18–0.75) | 0.39 (0.15–1.03) | |||||
| Recessive | AA-GA | 56 (94.9%) | 59 (75.6%) | 1.00 | 1.00 | 0.021 | |||
| GG | 3 (5.1%) | 19 (24.4%) | 0.17 (0.05–0.59) | 0.15 (0.02–1.17) | |||||
| Overdominant | AA-GG | 36 (61%) | 44 (56.4%) | 1.00 | 0.59 | 1.00 | 0.82 | ||
| GA | 23 (39%) | 34 (43.6%) | 0.83 (0.42–1.65) | 0.90 (0.34–2.34) | |||||
| rs352140 | Codominant | CC | 17 (28.8%) | 44 (56.4%) | 1.00 | 0.0051 | 1.00 | 0.017 | |
| CT | 32 (54.2%) | 26 (33.3%) | 3.19 (1.49–6.83) | 4.40 (1.41–13.75) | |||||
| TT | 10 (16.9%) | 8 (10.3%) | 3.24 (1.09–9.58) | 4.40 (0.97–20.02) | |||||
| Dominant | CC | 17 (28.8%) | 44 (56.4%) | 1.00 | 1.00 | ||||
| CT-TT | 42 (71.2%) | 34 (43.6%) | 3.20 (1.56–6.57) | 4.40 (1.47–13.13) | |||||
| Recessive | CC-CT | 49 (83%) | 70 (89.7%) | 1.00 | 0.25 | 1.00 | 0.33 | ||
| TT | 10 (16.9%) | 8 (10.3%) | 1.79 (0.66–4.85) | 1.94 (0.53–7.19) | |||||
| Overdominant | CC-TT | 27 (45.8%) | 52 (66.7%) | 1.00 | 0.014 | 1.00 | 0.03 | ||
| CT | 32 (54.2%) | 26 (33.3%) | 2.37 (1.18–4.75) | 2.89 (1.09–7.63) | |||||
aValues are the number of examined infants (%);
bAdjusted analysis was carried out for HCMV DNA copy number in whole-blood samples;
OR: odds ratio; 95% CI: 95% confidence interval; P, logistic regression model; NA: not available; Pc, The significance level after Bonferroni’s correction for multiple testing is 0.0045 (raw P-value/11).
The distribution of allele frequencies of TLR SNPs in infants with and without HCMV infection.
| Gene | SNP | Allele | Allele frequencies; n (%) | |||
|---|---|---|---|---|---|---|
| HCMV-infected | Uninfected | |||||
| rs121917864 | C | 118 (100) | 155 (99.4) | 0.3836 | 1.0000 | |
| T | 0 (0) | 1 (0.6) | ||||
| rs5743708 | G | 116 (98.3) | 156 (100) | 0.1027 | 0.8160 | |
| A | 2 (1.7) | 0 (0) | ||||
| rs3775290 | C | 78 (66.1) | 106 (67.9) | 0.7472 | 1.0000 | |
| T | 40 (33.9) | 50 (32.1) | ||||
| rs3775291 | C | 59 (50.0) | 116 (74.4) | |||
| T | 59 (50.0) | 40 (25.6) | ||||
| rs3775296 | C | 88 (74.6) | 129 (82.7) | 0.1012 | 0.6140 | |
| A | 30 (25.4) | 27 (17.3) | ||||
| rs179008 | A | 88 (74.6) | 109 (69.9) | 0.391 | 1.0000 | |
| T | 30 (25.4) | 47 (30.1) | ||||
| rs5741880 | G | 79 (67.0) | 108 (69.2) | 0.6879 | 1.0000 | |
| T | 39 (33.0) | 48 (30.8) | ||||
| rs5743836 | T | 116 (98.3) | 156 (100) | 0.1027 | 0.8160 | |
| C | 2 (1.7) | 0 (0) | ||||
| rs187084 | T | 70 (59.3) | 95 (60.9) | 0.7919 | 1.0000 | |
| C | 48 (40.7) | 61 (39.1) | ||||
| rs352139 | G | 29 (24.6) | 72 (46.2) | |||
| A | 89 (75.4) | 84 (53.8) | ||||
| rs352140 | C | 66 (55.9) | 114 (73.1) | |||
| T | 52 (44.1) | 42 (26.9) | ||||
aValues are the number of alleles (%); P, P-value was calculated from chi-square test; P, P-value for estimated alleles were generated from 1000 permutations using the expectation-maximization (EM) algorithm.
Haplotype analysis of TLR3 SNPs in children with and without HCMV infection.
| Haplotype | Frequency (%) | OR (95% CI) | ||||
|---|---|---|---|---|---|---|
| rs3775290 | rs3775291 | rs3775296 | HCMV-infected | Uninfected | ||
| C | C | C | 16.61 | 50.95 | 1.00 | NA |
| T | C | C | 13.47 | 21.32 | 1.94 (0.65–5.76) | 0.24 |
| C | T | C | 37.37 | 4.73 | 26.31 (5.30–130.68) | |
| C | T | A | 4.28 | 10.86 | 1.61 (0.17–15.69) | 0.68 |
| T | T | A | 1.22 | 4.36 | 20.91 (2.37–184.59) | 0.0071 |
| T | T | C | 7.13 | 5.69 | 2.78 (0.57–13.52) | 0.21 |
| C | C | A | 7.85 | 1.41 | 11.86 (0.91–154.56) | 0.061 |
| T | C | A | 12.07 | 0.68 | 2.42 (0.10–57.63) | 0.58 |
OR: odds ratio; 95% CI: 95% confidence interval; P, logistic regression model; NA: not available; P, The significance level after Bonferroni’s correction for multiple testing is 0.0063 (raw P-value/8).